AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

BROLUCIZUMAB

9 registrations across 7 African markets— 9 active

Markets with BROLUCIZUMAB

Recent registrations

Brand / ProductMarketHolderStatusExpires
VSIQQ🇿🇦South AfricaNovartis South Africa (Pty) LtdactiveJun 2031
Pagenax Solution for injection 120 mg/ml
Solution For Injection
🇰🇪KenyaNovartis Overseas Investments AGactiveSept 2028
Pagenax 120 mg/mL Solution for Injection**
Solution for intravitreal injection
🇳🇬NigeriaNovartis Nigeria LimitedactiveMar 2028
PAGENAX
SOLUTION; INJECTION
🇿🇼ZimbabweNOVARTIS OVERSEAS INVESTMENTS AGactiveMar 2028
Pagenax
Solution for injection
🇹🇿TanzaniaNVS Kenya Limitedactive
BROLUCIZUMAB
PARENTERAL ORDINARY VIALS
🇺🇬UgandaNVS KENYA LTDactive
PAGENAX® 120MG/ML SI I.VIT BTE(1FL + 1AIGUILLE) NOVARTIS
Solution pour injection
🇲🇬MadagascarNOVARTIS PHARMA SERVICESactive
BROLUCIZUMAB
PARENTERAL ORDINARY VIALS
🇺🇬UgandaNVS KENYA LTDactive
PAGENAX® 120MG/ML SI I.VIT BTE(1FL + 1AIGUILLE) NOVARTIS
Solution pour injection
🇲🇬MadagascarNOVARTIS PHARMA SERVICESactive

BROLUCIZUMAB in Africa — Regulatory Overview

BROLUCIZUMAB is registered across 7 African markets with 9 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Madagascar, Uganda, Kenya, South Africa and 3 more. AfricaRegulatory refreshes this data daily from official government sources.

Of the 9 registrations, 9 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.